Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829744) titled 'Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations' on Sept. 15.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai Zhongshan Hospital

Condition: Lung Cancer (NSCLC)

Intervention: Procedure: Surgical Resection

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 20, 2026

Target Sample Size: 190

To know more, visit https://clinicaltrials.gov/study/N...